Myasthenia gravis laboratory findings

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis laboratory findings

CDC on Myasthenia gravis laboratory findings

Myasthenia gravis laboratory findings in the news

Blogs on Myasthenia gravis laboratory findings

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis laboratory findings

Laboratory Findings

Laboratory findings consistent with the diagnosis of myasthenia gravis include:

Acetylcholine receptor antibodies:

One of the most important steps in confirming the diagnosis of myasthenia gravis is detecting AchR-Ab. About 85 percent of patients with generalized myasthenia gravis are seropositive for this Abs.(8-9) these antybodies are specific for myasthenia gravis but in rare cases we have false positive such as lambert-eaton, motor neuron disease, polymyositis(10-15-16) and even in the disease not related to myasthenia such as primary biliary cholangitis and systemic lupus erythematosus.(17-18) since the patient can become seronegative after immune modulating therapy, this test should be done before treatment. (12)

MuSK antibodies:

About 38 to 50 percent of patients with generalized disease, who are seronagative for AChR-Ab, have antibodies against muscle specific receptor tyrosine kinase (MuSK) (12-20 ta 26) these antibodies are not commonly seen in patients with well-established ocular myasthenia gravis. (28-29) This test can be useful in patients who have the typical presentation of myasthenia gravis but are negative for AChR-Ab.(21)

Anti-striated muscle antibodies:

These antibodies are present in about 80 percent of patients with thymoma and in 36 percent of myasthenia gravis patients overlay.(9) in patients with early onset myasthenia (20 to 50 years old) these antibodies are useful in detecting thymomas.(9,42)

Antibodies to titin:

Antibody to this protein which is an intracellular muscle protein is seen in about 95 percent of patients with myasthenia gravis and thymoma and in 50 percent of patients with myasthenia without thymoma.(45)

References

Template:WH Template:WS